Basic Drug Delivery Products
Advantages:
• Therapeutic agents are released locally from devices to provide maximum benefit where the treatment is most needed.
• Release rate and time period are customizable to optimize the clinical benefit.
• Optimized, site-specific dosages are administered without adverse effects common to systemic treatments.
Therapies:
• Antithrombogenic
• Antimicrobial
• Analgesics
• Vitamin/antioxidative
• Antiproliferative
• Angiogenesis factors
• Antiangiogenesis factors
Your protein/gene therapy for:
• Cell growth regulation
• Immune response regulation
• Skin/ organ tissue
• Vascular/coronary
• Cancer treatments
• Bone/cartilage/dental
• Neural/ocular system
• Let your imagination find the limits.
Sustained Release/Drug Attachment Technology
Sustained drug attachment and release therapies provide a framework to release therapeutic agents over an extended time period from a medical device.
US Patent 6096726 Sustained release of bioactive materials 2000
US Patent 6,683,062 Multicomponent Complex for Use with a Substrate 2004
US Patent Pending Sustained release one-step coating
Patented systems use crosslinking agents to bind the supporting polymers to each other for better strength and resistance to solvents, sterilizing materials, heat and body fluids. Crosslinkers also bind to functional groups on the surface to improve adhesion. For drug delivery applications it is possible to bind and immobilize pharmaceutical agents to the surface allowing for sustained release, or surface immobilization.
* Components in the coating for prolonged release depend on the functionality of additives- see us for more specific chemistries.
One step application of complex
#1 is surface, #2 is optional hydrophilic polymer, #3 are cleavable linkages, #4 is anchor provided by reactive polymer chains in the complex, #5 is embedded and exposed bioactive material
Two step application of complex
#1 is surface, #2 is primer layer of reactive anchor containing linker moiety /or linker moiety alone over reactive surface, #3 is cleavable linkage and #4 is bioactive material.
Release kinetics:
Dependence on crosslink density and hydrophilic content of polymer
Rapamycin release from aliphatic polycarbonate urethane in 37C PBS
Release Cumulative %
by HPLC |
Low hydrophilic
No Crosslinker |
Low hydrophilic
Crosslinker |
High Hydrophilic
Crosslinker |
| |
|
|
|
| 2 Hour |
4 |
0.3 |
1 |
| 1 Day |
6 |
0.4 |
2 |
| 4 Days |
6 |
0.4 |
2 |
| 1 Week |
6.4 |
0.4 |
2.5 |
| 2 Weeks |
6.4 |
0.4 |
2.5 |
To be tested High Hydrophilic, No crosslinke.r All samples showed measurable quantities released.
Applications Methods:
▪ Dip
▪ Pad/ Brush
▪ Spray
▪ Flow/Curtain
▪ Gravure/Roll/ Knife Over Roll
Instructions for use
MSDS Sheets for Drug Delivery Products
MSDS Sheets for Crosslinker A Products
Coatings2go, LLC is not responsible for the use of any of the information contained, or any product mentioned, in this document, and you must make your own determination of its suitability and completeness for your own use. You should conduct your own testing. All expressed and implied warranties, including any implied warranty of merchantability and warranty of fitness for a particular purpose and warranty arising out of the parties™ course of dealing are hereby disclaimed by C2g. The products are being sold "As Is". You are responsible for handling and disposal according to local, regional and federal regulations. C2g shall not be liable for any incidental or consequential damages. Nothing herein shall be construed as a license or sublicense to operate under any C2g or third party owned patent or as a warranty against infringement of any patent. By placing an order for any of these products and/or by accepting their delivery, the purchaser agrees to the above waivers.
